Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition

Indonesia Berita Berita

Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition
Indonesia Berita Terbaru,Indonesia Berita utama

Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.

  • 📰 Forbes
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 53%

Biogen will pay $172.50 per share in cash for Reata, which had a Thursday closing price of $108.

55), andThe company was founded in Plano, Texas in 2002 and focuses on antioxidative and anti-inflammatory drugsBiogen, a Massachusetts-based biotech company with a market cap of nearly $38 billion, has acquired three other companies in the last eight years. The $200 million

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

Forbes /  🏆 394. in İD
 

Indonesia Berita Terbaru, Indonesia Berita utama



Render Time: 2025-01-14 00:13:31